NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hexaell Biotech Co., Ltd.

Hexaell Biotech Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttp://hexaell.com/

Last Round

Series B++

Apr 25, 2026

Total Funding Raised

$52.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Hexaell Biotech Co., Ltd. is a biotechnology company that develops therapies for severe liver diseases using cell transdifferentiation technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

cell transdifferentiationbioartificial liveracute-on-chronic liver failureACLFcell therapyHepaCure Biocolumnliver diseaseregenerative medicineextracorporeal liver supporthepatocyte-like cellsclinical stage biotechdevice-drug combination producthiHepsInvestigational New DrugIND

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hexaell Biotech Co., Ltd. Comps

Public and private peers based on sector, stage, and business model.

Hexaell Biotech Co., Ltd. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hexaell Biotech Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B++Apr 25, 2026
Series BFeb 11, 2025
Series ADec 24, 2018

Hexaell Biotech Co., Ltd. Investors

Notable investors and investment history

Hexaell Biotech Co., Ltd. investors
InvestorRounds
Fuhui Venture CapitalSeries B++
Shanghai Healthcare CapitalSeries B
Shum Yip CapitalSeries B++
Zhongshan Cuiheng Group Co., Ltd.Series B++
Guangdong Yueke Financial GroupSeries B++
Hyfinity InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 25, 2026

    $14M round with participation from Shum Yip Capital and Fuho Capital.

  • Feb 11, 2025

    $31M round led by Shanghai Biomedical Industrial Equity Investment Fund

Hexaell Biotech Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hexaell Biotech Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hexaell Biotech Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2015
Last FundingApr 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.